Contact this trialFirst, we need to learn more about you.
Bruton's Tyrosine Kinase (BTK) Inhibitor
Acalabrutinib + Venetoclax for Chronic Lymphocytic Leukemia
Recruiting1 awardPhase 2
Seattle, Washington
This trial is testing a new cancer treatment combining acalabrutinib with venetoclax to see if it's more effective than either drug alone in treating patients with leukemia or lymphoma that has resisted or returned after treatment.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service